Lynch, K., Chapman, R., Keshav, S., Montano-Loza, A., Mason, A., Kremer, A., . . . Levy, C. (2019). Effects of vedolizumab in patients with primary sclerosing cholangitis and inflammatory bowel diseases. Elsevier.
Cita Chicago Style (17a ed.)Lynch, K., et al. Effects of Vedolizumab in Patients with Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases. Elsevier, 2019.
Cita MLA (9a ed.)Lynch, K., et al. Effects of Vedolizumab in Patients with Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases. Elsevier, 2019.
Precaución: Estas citas no son 100% exactas.